Abstract
Galectins,β-galactoside binding proteins, function in several physiological and pathological processes. The further evaluation of these processes as well as possible applications of galectins in diagnosis and therapy has raised high scientific interest. Therefore, easy and reliable test systems are necessary. Here we present the simple and cost-efficient production of recombinant human galectins as fusion proteins with SNAP-tag and fluorescent proteins. These constructs show binding specificities and oligomerisation properties generally comparable to recombinant galectins. Their direct fluorescence signal was utilised by ELISA-type assay and flow cytometry analysis with human and ovine mesenchymal stem cells (MSC). Flow cytometry demonstrated glycan mediated binding of His6-SNAP-YFP-Gal- 3 to both MSC types, which was specifically inhibited by lactose. Moreover, directed immobilisation by SNAP-tag technology onto benzylguanine- activated sepharose was utilised to prepare galectin affinity columns for glycoprotein analysis and purification. The SNAPtag directed coupling yielded up to three-fold higher binding capacities for the glycoprotein standard asialofetuin compared to nondirected coupled galectin suggesting improved functionality following directed coupling.
Keywords: Galectin-1, galectin-3, SNAP-tag, fusion protein, fluorescent protein, mesenchymal stem cells.
Current Pharmaceutical Design
Title:Fluorescent SNAP-Tag Galectin Fusion Proteins as Novel Tools in Glycobiology
Volume: 19 Issue: 30
Author(s): Christiane E. Kupper, Sophia Böcker, Hulong Liu, Carina Adamzyk, Julia van de Kamp, Tobias Recker, Bernd Lethaus, Willi Jahnen-Dechent, Sabine Neuss, Gerhard Muller-Newen and Lothar Elling
Affiliation:
Keywords: Galectin-1, galectin-3, SNAP-tag, fusion protein, fluorescent protein, mesenchymal stem cells.
Abstract: Galectins,β-galactoside binding proteins, function in several physiological and pathological processes. The further evaluation of these processes as well as possible applications of galectins in diagnosis and therapy has raised high scientific interest. Therefore, easy and reliable test systems are necessary. Here we present the simple and cost-efficient production of recombinant human galectins as fusion proteins with SNAP-tag and fluorescent proteins. These constructs show binding specificities and oligomerisation properties generally comparable to recombinant galectins. Their direct fluorescence signal was utilised by ELISA-type assay and flow cytometry analysis with human and ovine mesenchymal stem cells (MSC). Flow cytometry demonstrated glycan mediated binding of His6-SNAP-YFP-Gal- 3 to both MSC types, which was specifically inhibited by lactose. Moreover, directed immobilisation by SNAP-tag technology onto benzylguanine- activated sepharose was utilised to prepare galectin affinity columns for glycoprotein analysis and purification. The SNAPtag directed coupling yielded up to three-fold higher binding capacities for the glycoprotein standard asialofetuin compared to nondirected coupled galectin suggesting improved functionality following directed coupling.
Export Options
About this article
Cite this article as:
Kupper E. Christiane, Böcker Sophia, Liu Hulong, Adamzyk Carina, Kamp van de Julia, Recker Tobias, Lethaus Bernd, Jahnen-Dechent Willi, Neuss Sabine, Muller-Newen Gerhard and Elling Lothar, Fluorescent SNAP-Tag Galectin Fusion Proteins as Novel Tools in Glycobiology, Current Pharmaceutical Design 2013; 19 (30) . https://dx.doi.org/10.2174/1381612811319300017
DOI https://dx.doi.org/10.2174/1381612811319300017 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MDM2 and Human Malignancies: Expression, Clinical Pathology, Prognostic Markers, and Implications for Chemotherapy
Current Cancer Drug Targets Connecting Small Molecules to Nuclear Receptor Pathways
Current Topics in Medicinal Chemistry MicroRNAs in Glioblastoma: Role in Pathogenesis and Opportunities for Targeted Therapies
CNS & Neurological Disorders - Drug Targets Therapeutic Targeting of Apoptotic Pathways in Cancer
Current Drug Targets Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry New Targets for the Modulation of Radiation Response - Selective Inhibition of the Enzyme Cyclooxygenase 2
Current Medicinal Chemistry - Anti-Cancer Agents Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib
Current Cancer Drug Targets Modelling Human Disease with Pluripotent Stem Cells
Current Gene Therapy Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Oncogenic Signaling in Acute Myeloid Leukemia
Current Drug Targets A Review of Recent Patents Concerning Therapy of Respiratory Diseases Using Gene Silencing by RNAi (RISC) and EGS (RNAse P)
Recent Patents on Inflammation & Allergy Drug Discovery Insights into Targeting NEMO for Pharmacological Regulation
Current Drug Targets Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Therapeutics Based on microRNA: A New Approach for Liver Cancer
Current Genomics Recent Advances in Semisynthesis, Biosynthesis, Biological Activities,Mode of Action, and Structure-Activity Relationship of Podophyllotoxins:An Update (2008-2010)
Mini-Reviews in Medicinal Chemistry Study of HIV Resistance Mutations Against Antiretrovirals using Bioinformatics Tools
Current HIV Research Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Brain Tumour Stem Cells: Implications for Cancer Therapy and Regenerative Medicine
Current Stem Cell Research & Therapy Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014
Current Drug Targets